Sunshine Biopharma Inc WT (SBFMW)

$0.09 -0.06 (-42.77%)
Market Cap N/A
Revenue (ttm) 24.09M
Net Income (ttm) -4.51M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 2,800
Avg Vol 8,674
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 17%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pa...

Phone: 954 330 0684
Address:
333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, United States
Latest News on SBFMW
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering

May 18, 2026, 12:15 PM EDT - 11 minutes ago

Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering

Why Is Penny Stock Sunshine Biopharma (SBFM) Up Today?

2026-05-18T12:55:34.000Z - 3 hours ago

Why Is Penny Stock Sunshine Biopharma (SBFM) Up Today?

Sunshine Biopharma files to sell 5.825M common units

2026-05-12T21:20:04.000Z - 5 days ago

Sunshine Biopharma files to sell 5.825M common units

Sunshine Biopharma reports FY25 EPS ($1.44) vs. ($7.32) last year

2026-04-06T12:53:12.000Z - 6 weeks ago

Sunshine Biopharma reports FY25 EPS ($1.44) vs. ($7.32) last year

Sunshine Biopharma expects to reduce expenses by $2M-$3M in 2026

2026-04-06T12:52:43.000Z - 6 weeks ago

Sunshine Biopharma expects to reduce expenses by $2M-$3M in 2026

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

Apr 6, 2026, 8:30 AM EDT - 6 weeks ago

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Oct 28, 2025, 2:10 PM EDT - 7 months ago

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Sunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidone

2025-10-28T11:50:45.000Z - 7 months ago

Sunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidone

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Oct 28, 2025, 7:45 AM EDT - 7 months ago

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Sunshine Biopharma announces commercial launch of doxycycline in Canada

2025-10-20T11:50:37.000Z - 7 months ago

Sunshine Biopharma announces commercial launch of doxycycline in Canada

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Oct 20, 2025, 7:45 AM EDT - 7 months ago

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Sunshine Biopharma’s Nora Pharma launches pravastatin

2025-10-16T11:50:20.000Z - 7 months ago

Sunshine Biopharma’s Nora Pharma launches pravastatin

Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin

Oct 16, 2025, 7:45 AM EDT - 7 months ago

Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

Oct 14, 2025, 10:45 AM EDT - 7 months ago

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

Oct 14, 2025, 8:50 AM EDT - 7 months ago

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

Sunshine Biopharma allocates $5M for investment in bitcoin

2025-10-14T11:20:53.000Z - 7 months ago

Sunshine Biopharma allocates $5M for investment in bitcoin

Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience

Oct 14, 2025, 7:00 AM EDT - 7 months ago

Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience

Sunshine Biopharma, University of Arizona develop series of protease inhibitors

2025-10-09T12:26:07.000Z - 7 months ago

Sunshine Biopharma, University of Arizona develop series of protease inhibitors

Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

Oct 9, 2025, 8:00 AM EDT - 7 months ago

Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

Sunshine Biopharma’s Nora Pharma launches NIOPEG

2025-07-02T12:26:57.000Z - 11 months ago

Sunshine Biopharma’s Nora Pharma launches NIOPEG

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

Jul 2, 2025, 8:00 AM EDT - 11 months ago

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

Sunshine Biopharma launches generic gabapentin for neuropathic pain

2025-06-11T12:40:20.000Z - 1 year ago

Sunshine Biopharma launches generic gabapentin for neuropathic pain

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

Jun 11, 2025, 8:30 AM EDT - 1 year ago

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

May 15, 2025, 4:15 PM EDT - 1 year ago

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

Sunshine Biopharma launches generic Lurasidone for schizophrenia

2025-05-06T12:50:59.000Z - 1 year ago

Sunshine Biopharma launches generic Lurasidone for schizophrenia

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

May 6, 2025, 8:30 AM EDT - 1 year ago

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

Sunshine Biopharma launches Everolimus in Canada

2025-04-21T12:40:19.000Z - 1 year ago

Sunshine Biopharma launches Everolimus in Canada

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Apr 21, 2025, 8:30 AM EDT - 1 year ago

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Apr 3, 2025, 10:50 AM EDT - 1 year ago

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Apr 2, 2025, 1:20 PM EDT - 1 year ago

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Sunshine Biopharma announces results from studies on K1.1-mRNA-LNP product

2025-04-02T12:15:14.000Z - 1 year ago

Sunshine Biopharma announces results from studies on K1.1-mRNA-LNP product

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Sunshine Biopharma reports FY24 revenue $34.9M vs $24.1M last year

2025-04-01T21:15:21.000Z - 1 year ago

Sunshine Biopharma reports FY24 revenue $34.9M vs $24.1M last year

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Apr 1, 2025, 5:09 PM EDT - 1 year ago

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Sunshine Biopharma signs agreement for rights to market two generic antibiotics

2025-03-24T13:06:42.000Z - 1 year ago

Sunshine Biopharma signs agreement for rights to market two generic antibiotics

Sunshine Biopharma in strategic deal for new generic antibiotics in Canada

2025-03-24T12:30:07.000Z - 1 year ago

Sunshine Biopharma in strategic deal for new generic antibiotics in Canada

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Mar 10, 2025, 9:00 AM EDT - 1 year ago

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Jan 21, 2025, 8:00 AM EST - 1 year ago

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Jan 15, 2025, 8:00 AM EST - 1 year ago

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Dec 9, 2024, 7:30 AM EST - 1 year ago

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Sunshine Biopharma Launches a New Generic Prescription Drug

Dec 4, 2024, 4:05 PM EST - 1 year ago

Sunshine Biopharma Launches a New Generic Prescription Drug

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Dec 2, 2024, 8:00 AM EST - 1 year ago

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Nov 6, 2024, 8:00 AM EST - 1 year ago

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Sunshine Biopharma Announces Reverse Stock Split

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Reverse Stock Split

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Feb 15, 2024, 9:15 AM EST - 2 years ago

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Feb 13, 2024, 9:00 AM EST - 2 years ago

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Sunshine Biopharma Moves Principal Office to New York City

Dec 4, 2023, 8:30 AM EST - 2 years ago

Sunshine Biopharma Moves Principal Office to New York City

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Nov 13, 2023, 8:30 AM EST - 2 years ago

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Sep 21, 2023, 9:05 PM EDT - 2 years ago

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Aug 11, 2023, 8:30 AM EDT - 3 years ago

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

May 16, 2023, 2:15 PM EDT - 3 years ago

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

May 16, 2023, 9:58 AM EDT - 3 years ago

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

May 12, 2023, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

May 11, 2023, 9:00 AM EDT - 3 years ago

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Apr 5, 2023, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Feb 28, 2023, 7:30 AM EST - 3 years ago

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Feb 10, 2023, 7:35 AM EST - 3 years ago

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Sunshine Biopharma Announces Share Repurchase Program

Jan 19, 2023, 7:30 AM EST - 3 years ago

Sunshine Biopharma Announces Share Repurchase Program

Sunshine Biopharma's Annual Letter to Shareholders

Dec 20, 2022, 8:00 AM EST - 3 years ago

Sunshine Biopharma's Annual Letter to Shareholders

4 Stocks Meeting GuruFocus' Value Screens in December

Dec 5, 2022, 5:46 PM EST - 3 years ago

4 Stocks Meeting GuruFocus' Value Screens in December

RM CACC WFG